Articles related to IMMUNOTHERAPY

A phase 3 trial in extensive-stage small cell lung cancer found that adding concurrent thoracic radiotherapy to chemoimmunotherapy did not improve survival outcomes and was associated with higher toxicity. Investigators reported more adverse events and treatment-related deaths, raising safety concerns about this combination strategy.

An engineered probiotic strain delivering a modified IL-2 therapy directly within pancreatic tumors slowed tumor growth and enhanced immune activity in preclinical models. Combination studies with chemotherapy, radiotherapy, and immunotherapy showed additional activity, though human data are not yet available.

“The extended-hours model was effective… early morning dose, in-center observation, overnight remote monitoring equipment, and next-day follow-up cut the need for extended shifts and differential pay.”

A gynecologic oncologist reviews the current role of immune checkpoint inhibition across locally advanced and recurrent cervical cancer settings, including KEYNOTE-A18 survival data, key regulatory distinctions, and unanswered sequencing questions.

“By comparing current standard-of-care treatments with a potential novel therapy in refractory mCRC, this review underscores existing gaps and highlights future research priorities while awaiting randomized data.” – Elisabetta Bengala, MD, Regina Elena National Cancer Institute, Rome, Italy

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026